Successful long-term treatment of cushing disease with mifepristone (RU486)

Endocrine Practice

Volumn 18, Issue 5, 2012, Pages

  Basina, Marina ^a   Liu, Hau ^a   Hoffman, Andrew R ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; HYDROCORTISONE; KETOCONAZOLE; MEDROXYPROGESTERONE ACETATE; METYRAPONE; MIFEPRISTONE; POTASSIUM CHLORIDE; PRASTERONE SULFATE; SPIRONOLACTONE;

ABDOMEN; ACTH SECRETING ADENOMA; ADOLESCENT; ADRENALECTOMY; AMENORRHEA; ARTICLE; BIOCHEMISTRY; CANCER INVASION; CANCER SURGERY; CASE REPORT; CAVERNOUS SINUS; CLINICAL FEATURE; CUSHING DISEASE; CYBERKNIFE; CYTOPLASM; DEXAMETHASONE SUPPRESSION TEST; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERTENSION; HYPOKALEMIA; HYPOPHYSIS; IMAGING; LONG TERM CARE; MENARCHE; MENSTRUAL IRREGULARITY; MENSTRUATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; PRESCRIPTION; RADIATION DOSE; STRIA; THIGH; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT FAILURE; URINARY EXCRETION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84867361736     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11391.CR     Document Type: Article

References (20)

1. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: A consensus state-ment. J Clin Endocrinol Metab. 2003;88:5593-5602.
2. Arnaldi G, Boscaro M. Pasireotide for the treatment of Cushing's disease. Expert Opin Investig Drugs. 2010;19: 889-898.
3. Clark RD. Glucocorticoid receptor antagonists. Curr Top Med Chem. 2008;8:813-838.
4. Sartor O, Cutler GB Jr. Mifepristone: Treatment of Cushing's syndrome. Clin Obstet Gynecol. 1996;39: 506-510.
5. Jung-Testas I, Baulieu EE. Inhibition of glucocorticoste-roid action in cultured L-929 mouse fibroblasts by RU 486, a new anti-glucocorticosteroid of high affinity for the glu-cocorticosteroid receptor. Exp Cell Res. 1983;147:177-182.
6. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepris-Tone): Mechanisms of action and clinical uses. Annu Rev Med. 1997;48:129-156.
7. Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol. 2007;157:561-569.
8. Lamberts SW, Koper JW, de Jong FH. The endocrine effects of long-Term treatment with mifepristone (RU 486). J Clin Endocrinol Metab. 1991;73:187-191.
9. Bertagna X, Escourolle H, Pinquier JL, et al. Administration of RU 486 for 8 days in normal volunteers: Antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab. 1994;78: 375-380.
10. Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton JP. Pituitary-Adrenal response to the anti-glucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab. 1986;63:639-643.
11. Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61: 536-540.
12. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-Term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab. 2001;86:3568-3573.
13. Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009;160:1003-1010.
14. Chrousos GP, Laue L, Nieman LK, et al. Glucocorticoids and glucocorticoid antagonists: Lessons from RU 486. Kidney Int Suppl. 1988;26:S18-S23.
15. Castinetti F, Conte-Devolx B, Brue T. Medical treatment of Cushing's syndrome: Glucocorticoid receptor antagonists and mifepristone. Neuroendocrinology. 2010;92(Suppl 1): 125-130.
16. Funder JW. Apparent mineralocorticoid excess. Endocrinol Metab Clin North Am. 1995;24:612-621.
17. Kalinyak JE, Dorin RI, Hoffman AR, Perlman AJ. Tissue-specific regulation of glucocorticoid receptor mRNA by dexamethasone. J Biol Chem. 1987;262:10441-10444.
18. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progester-one antagonists: Mechanisms of action and clinical applica-Tions. Hum Reprod Update. 2005;11:293-307.
19. Spitz IM. Clinical utility of progesterone receptor modula-Tors and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009;21:318-324.
20. Mutter GL, Bergeron C, Deligdisch L, et al. The spec-Trum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591-598.